Market Overview
Compass Therapeutics (CMPX) experienced a modest decline of 0.24 % during the 24‑hour trading period that ended at 12:15 PM Central Europe on Wednesday, 21 January 2026. At the close, the share price was approximately USD 0.83 on major exchanges.
Key Market Metrics
| Item | Value |
|---|---|
| Shares Outstanding | 180.1 million |
| Market Capitalisation | USD 150.4 million |
| 24‑Hour Trading Volume | USD 1.6 million |
| Year‑to‑Date Performance (since last month‑end) | Down 54.23 % |
| 200‑Day Simple Moving Average | USD 3.37 |
| 52‑Week High | USD 6.88 (02 March 2026) |
| 52‑Week Low | USD 0.82 (20 October 2026) |
Compass Therapeutics is a clinical‑stage, oncology‑focused biopharmaceutical company headquartered in Boston, Massachusetts. The company develops proprietary antibody‑based therapeutics for cancer and other human diseases and is listed on the Nasdaq exchange. Additional information can be found on the company website at www.compasstherapeutics.com .
Comparative Performance of Related Stocks
The following table summarizes the 24‑hour performance of selected peers and key market metrics:
| Symbol | 24‑Hour Change | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|
| RILY (Brc) | +0.23 % | USD 4.45 | USD 178.5 million | 0.37 |
| BGS (B&g Foods) | –0.45 % | USD 2.19 | USD 178.8 million | – |
| IVVD (Invivyd) | +4.43 % | USD 0.64 | USD 179.8 million | – |
| JRVR (James River I) | +0.26 % | USD 3.87 | USD 178.5 million | 7.54 |
| XGN (Exagen) | –0.27 % | USD 7.41 | USD 180 million | – |
Notable Corporate Events (Exagen Inc.)
On 20 October 2026, Exagen Inc. filed a Form 4 reporting that Jorey Chernett, a ten‑percent owner, increased his holdings of the company’s common stock through a purchase transaction. The filing confirmed that the shares were bought at a weighted average price and that Chernett’s stake has grown. Earlier, on 16 October, President and CEO John Aballi disclosed a sale of shares to meet tax‑withholding obligations related to restricted‑stock‑unit vesting. The transaction involved a significant number of shares but was not deemed a discretionary sale. No additional material corporate actions were reported.
Summary
Compass Therapeutics continues to trade in a highly volatile range, with a significant decline over the past month. While the stock remains deeply discounted relative to its 52‑week high, its recent performance mirrors broader trends in the biopharmaceutical sector, as evidenced by the mixed movements of peer companies. Investors should monitor upcoming clinical data releases and regulatory updates for potential catalysts that could influence the company’s valuation.